Circio Holding ASA

BATS-CHIXE:CRNAO Stock Report

Market Cap: NOK 20.5m

Circio Holding Past Earnings Performance

Past criteria checks 3/6

Circio Holding's earnings have been declining at an average annual rate of -12.7%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 32% per year.

Key information

-12.7%

Earnings growth rate

19.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate32.0%
Return on equityn/a
Net Margin7,722.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Circio Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:CRNAO Revenue, expenses and earnings (NOK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24092315
31 Mar 240-512932
31 Dec 230-1113550
30 Sep 2310-4464262
30 Jun 2310-4494566
31 Mar 2310-4404859
31 Dec 2210-4335347
30 Sep 220-1075341
30 Jun 220-1105443
31 Mar 220-1065438
31 Dec 210-984937
30 Sep 210-984873
30 Jun 210-974663
31 Mar 210-1054454
31 Dec 201-1084445
30 Sep 203-117430
30 Jun 203-120420
31 Mar 203-132430
31 Dec 192-148450
30 Sep 190-153520
30 Jun 190-162560
31 Mar 190-153590
31 Dec 180-147610
30 Sep 180-139600
30 Jun 180-132600
31 Mar 180-129570
31 Dec 170-122530
30 Sep 170-121530
30 Jun 170-119520
31 Mar 170-118510
31 Dec 160-122540
30 Sep 160-134530
30 Jun 160-137560
31 Mar 160-117480
31 Dec 150-92370
30 Sep 150-57230
30 Jun 150-32110
31 Mar 150-2280
31 Dec 140-1860
30 Sep 14-3-1220
30 Jun 14-1-1020
31 Mar 140-930
31 Dec 130-830

Quality Earnings: CRNAO has high quality earnings.

Growing Profit Margin: CRNAO became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CRNAO has become profitable over the past 5 years, growing earnings by -12.7% per year.

Accelerating Growth: CRNAO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CRNAO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.8%).


Return on Equity

High ROE: CRNAO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/17 05:13
End of Day Share Price 2024/06/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Circio Holding ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Geir HolomDNB Markets
Jonas PeciulisEdison Investment Research